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Functional analysis of the protein phosphatase activity of PTEN
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In vitro, the tumour suppressor PTEN (phosphatase and tensin
homologue deleted on chromosome 10) displays intrinsic
phosphatase activity towards both protein and lipid substrates.
In vivo, the lipid phosphatase activity of PTEN, through which
it dephosphorylates the 3 position in the inositol sugar of phos-
phatidylinositolderivatives,isimportantforitstumoursuppressor
function; however, the signiﬁcance of its protein phosphatase
activity remains unclear. Using two-photon laser-scanning
microscopy and biolistic gene delivery of GFP (green ﬂuorescent
protein)-tagged constructs into organotypic hippocampal slice
cultures, we have developed an assay of PTEN function in
living tissue. Using this bioassay, we have demonstrated that
overexpression of wild-type PTEN led to a decrease in spine
density in neurons. Furthermore, it was the protein phosphatase
activity, but not the lipid phosphatase activity, of PTEN that was
essential for this effect. The ability of PTEN to decrease neuronal
spine density depended upon the phosphorylation status of serine
and threonine residues in its C-terminal segment and the integrity
of the C-terminal PDZ-binding motif. The present study reveals
a new aspect of the function of this important tumour suppressor
andsuggestthat,inadditiontodephosphorylatingthe3positionin
phosphatidylinositol phospholipids, the critical protein substrate
of PTEN may be PTEN itself.
Key words: organotypic hippocampal slice culture, PDZ domain,
phosphatase and tensin homologue deleted on chromosome
10 (PTEN), protein phosphatase, spine density, two-photon
laser-scanning microscopy.
INTRODUCTION
PTEN (phosphatase and tensin homologue deleted on
chromosome 10; also known as MMAC1 and TEP1) is the
tumour suppressor encoded by the chromosome 10q23 locus
[1]. It is one of the most frequently lost or mutated tumour
suppressors in human cancer and is generally associated with
advancedandmetastaticdisease[1].GermlinemutationsinPTEN
are also associated with a series of autosomal-dominant cancer-
predisposition syndromes, including Cowden, Bannayan–Riley–
RuvalcabaandProteussyndromesandLhermitte–Duclosdisease,
which have been categorized together as the PTEN harmartoma
tumour syndromes [2]. These syndromes, which are associated
withtheformationofmultiplebenigntumours(harmartomas)and
increased rates of malignant breast and thyroid tumours, reveal
that even minor disruption of PTEN function can increase the risk
of cancer [3]. More recently, changes in PTEN function have also
been implicated in non-neoplastic disease, including Alzheimer’s
and Parkinson’s diseases, and other neuronal disorders [4,5].
Some PTEN harmartoma tumour syndrome patients develop
macrocephaly, an abnormal enlargement of the head, which led to
recognitionofPTENasagenemarkerforautisticbehaviour[4,5].
Taken together, these observations emphasize the diverse roles of
PTEN in vivo and highlight the importance of understanding its
function and the mechanisms by which it exerts its effects.
The PTEN protein comprises 403 amino acid residues and
features a PTP (protein tyrosine phosphatase) domain at the N-
terminal segment of the protein (Figure 1). Structural studies
revealed an unusual architecture of the active site of PTEN,
which is sufﬁciently large to accommodate the sugar headgroup
of inositol phospholipids as a substrate [6]. In fact, there are
now extensive lines of evidence that illustrate the importance
of this lipid phosphatase activity of PTEN, in particular the
ability to antagonize PI3K (phosphoinositide 3-kinase) function
by dephosphorylating the 3 position in the inositol sugar ring,
for its tumour suppressor function and its ability to control
cell proliferation, survival and motility [1]. Considering the
importance of PTEN in a broad array of functions in vivo, one
would anticipate that its activity would be tightly regulated.
In fact, there are additional prominent structural features of
the PTEN protein that are important in this regard. The PTP
domain forms an extensive interface with the C2 domain, which
serves to bind phospholipid membranes [6]. The C-terminus of
the protein, which is also important for its tumour suppressor
function, is characterized by multiple phosphorylation sites
and a binding motif (-Thr-Lys-Val-COOH) for PDZ domain-
containing proteins [1]. Several protein–protein interactions
involving binding partners of the C-terminus of PTEN have the
potential to be of regulatory signiﬁcance [7,8].
A signiﬁcant development that facilitated the appreciation of
the physiological importance of PTEN has been the generation
of sophisticated animal models to deﬁne the consequences of the
loss of function of this phosphatase [9]. In addition to providing
a deeper understanding of its role as a tumour suppressor,
animal models have revealed the importance of PTEN in
neuronal systems, including insights into the structural and
behavioural consequences of its loss of function. For example,
conditionalknockoutofPTENinspeciﬁcneuronalpopulationsof
the cerebral cortex and hippocampus generated mice that display
hyperactivity and increased anxiety-like behaviour, coupled with
deﬁcits in social interactions, consistent with a linkage to atypical
autism spectrum disorders [10]. These behavioural changes
coincided with structural changes within the brain, including
macrocephaly. The mice also displayed disruption of axonal and
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Figure 1 The domain structure of PTEN
SchematicrepresentationtoillustratethemajordomainsofPTEN,thecatalyticandC2domains
and the C-terminal PDZ-binding motif (PDZB). The signature motif of the catalytic domain is
shown, with the residues that were altered in the phosphatase activity mutants highlighted in
bold. The acidic sequence motif in the C-terminal segment of the protein is also shown with the
four phosphorylation sites highlighted in bold.
dendriticgrowth,includinghypertrophythatwascharacterizedby
increased density of spines, the structures that underlie functional
neural connections [10,11]. Importantly, these effects were cell
autonomous, which suggested that it may be possible to use spine
density as a biological read-out of PTEN function.
Following its identiﬁcation as the 10q23 tumour suppressor, as
predicted by its sequence, we demonstrated that PTEN possessed
intrinsic phosphatase activity towards protein substrates in vitro
[12].Inanimportantbreakthroughfortheﬁeld,itbecameapparent
thatPTENalsohadtheabilitytodephosphorylatethelipidsecond
messenger molecule PtdIns(3,4,5)P3, which suggested a potential
mechanism for tumour suppression as an antagonist of PI3K-
dependent signalling [13]. Initially, we had characterized the
enzymatic activity of disease-derived mutations in PTEN, which
revealed the properties of the G129E mutant that was identiﬁed
originally in the germline of patients with Cowden syndrome
[14]. This mutant maintains the ability to dephosphorylate
protein substrates, but its ability to dephosphorylate inositol
phospholipids is impaired, thus highlighting the importance
of the lipid phosphatase activity for PTEN tumour suppressor
function [14]. Nevertheless, the signiﬁcance of its protein
phosphatase activity remains unknown and represents a gap in
our understanding of the function of this important regulator
of cell signalling. Such PTEN mutants form the basis for our
experimental strategy to deﬁne the signiﬁcance of this activity.
In the present paper, we describe the development of a
biological assay of PTEN function. The approach used two-
photon laser-scanning microscopy to monitor the effects of
biolistically delivered GFP (green ﬂuorescent protein)-tagged
PTEN constructs into organotypic slices of the hippocampus.
Through this approach we observed that expression of wild-type
PTEN led to a decrease in spine density, which could be used
as a read-out of PTEN function. Comparison of the effects of
expressing various PTEN mutants revealed that the decrease in
density of neuronal spines in cultured hippocampal slices was
triggered by its protein phosphatase activity, rather than its ability
to dephosphorylate inositol phospholipids. The results of the
present study illustrate that dephosphorylation of the PTEN C-
tail (C-terminal tail), which is a substrate of PTEN itself, is of
regulatory signiﬁcance in the control of spine density in this
system, perhaps through controlling interactions between PTEN
andPDZdomain-containingproteins.Overall,ourresultssuggest
that PTEN autodephosphorylation may be a critical event in this
process; thus a major protein substrate for PTEN may be PTEN
itself.
EXPERIMENTAL
Plasmids
All GFP–PTEN constructs were generated using the GFP–
C2 vector (Clontech) to produce N-terminally GFP-tagged
proteins. GFP–PTEN(C124S)-4A and GFP–PTEN(C124S)-4D
were generated from GFP–PTEN-4A or GFP–PTEN-4D by site-
directed mutagenesis using the QuikChange® II site-directed
mutagenesis kit (Stratagene).
Hippocampal slice culture and transfection
Hippocampal slices were prepared from P7 rats as described
previously [15]. Animal experimentation was carried out
according to the Animal Care and Use Committee of Cold Spring
HarborLaboratoryguidelines(protocolnumber08-04-02).Genes
were delivered at 6 DIV (days in vitro) using biolistic gene
transfer [180 psi (1 psi=6.9 kPa), Helios Gene Gun, Bio-Rad
Laboratories] [16]. Plasmid DNAs were coated on to 1.6 μm
gold beads; co-expression was achieved by coating the beads
with DsRed (Discosoma red ﬂuorescent protein) and GFP–PTEN
or one of the GFP–PTEN mutant constructs. For a standard
preparation, we used 14 μg of DsRed DNA and 36 μg of GFP–
PTEN wild-type or mutant DNA with 12.5 mg of gold beads.
Two-photon laser-scanning microscopy and image analysis
The procedures were based on those described in [17–19]. At
48 h after transfection, slices were perfused with ACSF [artiﬁcial
cerebrospinal ﬂuid; 127 mM NaCl, 25 mM NaHCO3,1 . 2 5m M
NaH2PO4, 25 mM D-glucose, 2.5 mM KCl, 4 mM MgCl2,
2m MC a C l 2 and 1 mM MgSO4 (pH 7.28 at 23◦C) aerated with
95% O2/5% CO2] at room temperature (23◦C). Transfected
CA1 pyramidal neurons were identiﬁed by epiﬂuorescence
illumination. For each cell, a standard region encompassing
the initial bifurcation of the CA1 neuron was chosen for
data acquisition and two to three segments of apical dendrites
were sampled. High-resolution three-dimensional image stacks,
consisting of sections of 512 pixels×512 pixels were collected in
0.5 μm steps on a custom-built instrument based on a Fluoview
laser-scanningmicroscope(OlympusAmerica)withanexcitation
wavelength of 910 nm. All clear protrusions emanating laterally
fromthedendriticshaft,irrespectiveofshape,werecountedinthe
DsRedimagesandthespinedensitywasmeasuredmanuallyusing
custom MATLAB software [18] by an observer who was blinded
to genotype. All images in the Figures are projections of three-
dimensional stacks. Values are means+ −S.E.M., and statistical
signiﬁcance was determined using Student’s t test. Expression
levels of GFP-tagged proteins were compared by measuring the
ﬂuorescence intensity of single spines at a ﬁxed region of interest,
standardized according to the co-transfected cytoplasmic marker
DsRed. No signiﬁcant differences in expression were detected.
PTEN puriﬁcation, PTEN C-tail preparation and PTEN phosphatase
assays
GST–PTEN, GST–PTEN G129E, GST–PTEN C124S and GST–
PTENY138Lwereexpressedandpuriﬁedasdescribedpreviously
[12]. PTEN C-tail peptide (DHYRYSDTTDSDPENE, 0.5 mM)
wasphosphorylatedwithrecombinantcaseinkinaseII(agiftfrom
DrD.Litchﬁeld,DepartmentofBiochemistry,SchulichSchoolof
Medicine and Dentistry, University of Western Ontario, London,
Ontario, Canada) in a reaction mixture consisting of 50 mM
Tris/HCl (pH 7.6), 2 mM DTT (dithiothreitol), 150 mM NaCl,
10 mM MgCl2, 0.2 mg/ml BSA and 0.1 mM [γ-
32P]ATP (speciﬁc
activity 100 c.p.m./pmol) and incubated at 30◦C for 10 min.
Phosphorylated peptide then was puriﬁed with minitrap G-10
columns(GEHealthcare,cataloguenumber28-9180-10).Puriﬁed
peptide substrates were freeze-dried to dryness and resuspended
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inphosphataseassaybuffer,consistingof50 mMHepes(pH 7.0),
10 mM MgCl2 and 10 mM DTT. The standard phosphatase assay
contained5 μMsubstrate,50 mMHepes(pH 7.0),10 mMMgCl2
and 10 mM DTT. The reaction was initiated by the addition
of 0.2 μg of enzyme to pre-warmed (30◦C) substrate mixture,
resulting in a ﬁnal volume of 30 μl. The reactions were allowed
to proceed at 30◦C for various times up to 15 min and stopped by
theadditionofasuspensionofactivatedcharcoalin900 mMHCl,
90 mM sodium pyrophosphate and 2 mM sodium phosphate.
Protein extraction, immunoprecipitation and immunoblotting
GFP or GFP-tagged PTEN constructs were transfected into
HEK (human embryonic kidney)-293 cells. At 2 days after
transfection, cells were harvested in ice-cold lysis buffer
[20 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM2-glycerophosphate,1 mMsodiumorthovanadate,1 μg/ml
leupeptin and 1 mM PMSF]. Protein extracts (1 mg) were
incubated with a mouse anti-GFP antibody (Invitrogen) bound
to magnet beads (Invitrogen) overnight at 4◦C. Antibodies used
for immunoblotting [anti-phospho-PTENantibody and anti-(total
PTEN) antibody] were from Cell Signaling Technology.
RESULTS
Phosphatase activity of PTEN and regulation of dendritic spine
density
We developed a tissue assay of PTEN function to test the
signiﬁcance of its protein phosphatase activity and extended this
assay to discover non-catalytic functions of PTEN. We used a
biolistic particle delivery system to express plasmids encoding
GFP-tagged PTEN (to visualize PTEN expression) and DsRed
(used as a cell marker) in individual neurons in organotypic slices
of the hippocampus. At 2 days after transfection, two-photon
laser-scanning microscopy was performed to generate whole-
cell images, which revealed that GFP–PTEN was distributed
throughoutCA1pyramidalneurons,includinginthedendritesand
spines (Figure 2A). The levels of expression of the various GFP-
tagged forms of the PTEN protein were consistent (Figure 2B).
The use of two-photon microscopy allowed us to image
apical dendrites and to analyse spine density. Importantly,
these experiments were conducted blind with respect to the
identity of the GFP–PTEN constructs that were being expressed.
Consistent with the increase in spine density that has been shown
to accompany the loss of PTEN in knockout mouse models
[10,11], we observed that expression of wild-type GFP–PTEN
resulted in a dramatic decrease in spine density compared with
the control neurons transfected with GFP alone. Furthermore,
GFP–PTEN(C124S), the catalytically dead mutant form of the
phosphatase [12], which differs from the wild-type enzyme by a
single atom, was without apparent effect. These data demonstrate
that spine density can be used as a measure of PTEN activity
in vivo. Furthermore, this decrease in spine density was also
observed in neurons expressing the GFP–PTEN(G129E) mutant,
in which the protein phosphatase activity is maintained but lipid
phosphatase activity is attenuated (Table 1) [14]. Interestingly,
expression of GFP–PTEN(Y138L), the converse mutant in which
lipid phosphatase activity is preserved, but protein phosphatase
activity is attenuated [20], did not alter spine density (Figure 3).
These results reveal striking speciﬁcity in the effects of the PTEN
mutants when expressed at similar levels in the context of an
organotypicbrainsliceculturesystem.Furthermore,theyindicate
Figure 2 Expression of GFP–PTEN in hippocampal CA1 pyramidal neurons
(A) Top panel: a schematic representation of the position of dendrites imaged in the neurons.
ExamplesofGFP–PTEN/DsRedﬂuorescenceofatransfectedhippocampalCA1neuron(middle
panels) and of apical dendrites in a transfected hippocampal CA1 neuron (bottom panels)
are presented. White arrows highlight the spines. (B) Comparison of the levels of expression of
thevariousGFP-taggedformsofPTEN,madebymeasurementofﬂuorescenceintensityofsingle
spines at a ﬁxed region of interest, standardized according to the co-transfected cytoplasmic
marker DsRed.
thatinCA1hippocampalpyramidalneurons,expressionofPTEN
regulated spine density in a manner that was dependent on its
protein phosphatase, but not its lipid phosphatase, activity.
Dephosphorylation of PTEN, by PTEN
A striking feature of the protein phosphatase activity of PTEN
is its preference for acidic substrates [12]. Inspection of
the sequence surrounding the cluster of phosphorylation sites
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Table 1 Summary of the enzymatic properties of PTEN mutants
Mutant Lipid phosphatase activity Protein phosphatase activity
GFP–PTEN Yes Yes
GFP–PTEN(C124S) No No
GFP–PTEN(G129E) No Yes
GFP–PTEN(Y138L) Yes No
Figure 3 Effect of PTEN expression on spine density in CA1 pyramidal
neurons requires its protein, but not lipid, phosphatase activity
Representative images of apical dendrites from biolistically transfected CA1 pyramidal neurons
expressing the indicated forms of PTEN in organotypic slice cultures of rat hippocampus. Scale
bar=10μm.Thehistogramshowsquantiﬁcationoftheeffectsofeachplasmidonspinedensity
andeachbarispresentedbelowtheappropriateimage(means+ −S.E.M.,*P < 0.0001).n=8
cells for each group.
in the C-terminal segment of PTEN revealed that this portion
of the molecule is rich in acidic residues (Figure 1). Therefore we
testedthepossibilitythatapeptidemodelledonthissequence,and
phosphorylated in vitro by casein kinase 2α, may be recognized
as a substrate by PTEN. As shown in Figure 4(A), both wild-type
and G129E mutant forms of PTEN dephosphorylated the PTEN
C-tail peptide, whereas the inactive PTEN(C124S) and protein
phosphatase-deﬁcient PTEN(Y138L) mutants did not. These
resultsareconsistentwiththemodelthatPTENdephosphorylates
itself.
Furthermore, we have investigated the ability of PTEN
to autodephosphorylate by determining the phosphorylation
status of the various forms of PTEN in lysates of HEK-293
cells. At 2 days post-transfection, we used anti-GFP antibodies
to immunoprecipitate PTEN and then immunoblotted with
phospho-speciﬁc antibodies directed against the C-terminal
cluster of phosphorylation sites. In contrast with inactive
GFP–PTEN(C124S) or protein phosphatase-deﬁcient GFP–
PTEN(Y138L), which were recognized by the phospho-speciﬁc
antibodies, the signal from wild-type PTEN and the protein
phosphatase-active lipid phosphatase-deﬁcient mutant, GFP–
PTEN(G129E) was decreased (Figure 4B). Importantly, only
those PTEN alleles that could dephosphorylate the synthetic
Figure 4 PTEN displays potential for autodephosphorylation
(A) PTEN dephosphorylated the C-tail peptide in vitro. Puriﬁed wild-type and mutant PTEN
was tested for protein phosphatase activity using [32P]Pi-labelled phosphorylated PTEN C-tail
peptide as substrate. Activity is expressed as pmol of [32P]Pi released/min per mg of enzyme.
Theassay was performedin triplicate. Values are means+ −S.D. (B) The phosphorylationstatus
of the C-tail segment of PTEN in cells coincided with protein phosphatase activity. GFP or
GFP-tagged PTEN constructs were transfected into HEK-293 cells and the expressed proteins
were immunoprecipitated (IP) with an antibody against GFP, followed by immunoblotting ﬁrst
with an antibody against phospho-PTEN (Ser380/Thr382/383) (top panel) and secondly with an
antibody against total PTEN (bottom panel).
C-tail peptide in vitro also displayed reduced anti-phospho-
PTEN reactivity when isolated from cells. Therefore these
results are consistent with the ability of PTEN to utilize its
protein phosphatase activity to dephosphorylate its C-terminal
segment.
Effects of phosphorylation site-mutant forms of PTEN on dendritic
spine density
As phosphorylation of the C-terminal portion of PTEN has
been proposed to exert a regulatory inﬂuence, we sought to
exploit our bioassay to examine the importance of the C-terminal
phosphorylation sites for the effects of PTEN on spine density.
We constructed inactive (C124S) PTEN mutants in which the
four phosphorylation sites (Ser
380,T h r
382,T h r
383 and Ser
385)
were converted into non-phosphorylatable alanine residues (4A
mutation), to mimic the dephosphorylated form of the protein,
or to negatively charged aspartate residues (4D mutation), de-
signed to mimic phosphorylated PTEN. Surprisingly, even in the
absence of any intrinsic phosphatase activity in the protein,
expression of the PTEN(C124S)-4A mutant led to a signiﬁcant
decrease in spine density (Figure 5A). In contrast, neither
the C124S mutant, which would be incapable of catalysing
autodephosphorylation, nor the (C124S)-4D mutant, which
potentially mimics the phosphorylated state of PTEN, led to a
decrease in spine density. Similarly, the 4D mutation blocked the
effects of wild-type PTEN (Figure 5B). These results indicate
that rather than phosphatase activity, it was the phosphorylation
status of these C-terminal sites, speciﬁcally the absence of
phosphate, that was important for the ability of PTEN to reduce
dendritic spine density, indicating the presence of a heretofore
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Figure5 EffectofmutatingphosphorylationsitesintheC-terminalsegment
of wild-type and C124S inactive mutant forms of PTEN on its ability to reduce
spine density
Representative images of apical dendrites from biolistically transfected CA1 pyramidal neurons
expressing the indicated forms of PTEN in organotypic slice cultures of rat hippocampus.Scale
bar=10μm. The histograms show quantiﬁcation of the effects of each plasmid on spine
density (means+ −S.E.M., *P < 0.0001). n=8 cells for each group.
uncharacterized function of PTEN that is regulated by its
phosphorylation status.
Identiﬁcation of other structural features of PTEN that are important
for the decrease in dendritic spine density
In addition to the catalytic domain, PTEN contains a C2 domain
and a C-terminal tail. The C2 domain of PTEN lacks residues
that are important for the normal Ca
2+-binding function of such
domains, but it has been shown to bind phospholipid membranes
in vitro [6]. In addition, it has been shown that PTEN can inhibit
cellmigrationviaitsC2domain,independentlyofitsfunctionasa
lipid phosphatase [21]. In light of the importance of the PTEN C2
domain, we examined its effects on spine density in our system.
In contrast with these previous studies, we observed a minimal
decrease in spine density following expression of the GFP–PTEN
C2 domain (Figure 6).
In parallel, we examined the importance of other features of
the non-catalytic portion of PTEN, speciﬁcally the C-terminal
Figure 6 Expression of the PTEN C2 domain alone did not reduce the spine
density in CA1 pyramidal neurons
Effects on spine density of wild-type and isolated PTEN C2 domain were compared. The top
panels are representative images of apical dendrites of biolistically transfected CA1 pyramidal
neuronsexpressingtheindicatedformsofPTENinorganotypicsliceculturesofrathippocampus.
Scalebar=10μm.Thehistogramshowsquantiﬁcationoftheeffectsofeachplasmidonspine
density (means+ −S.E.M., *P < 0.0001). n=8 cells for each group.
PDZ-binding motif. First, we expressed GFP–PTEN(1–399stop),
a mutant that lacks the C-terminal ﬁve residues. Interestingly,
we observed that, unlike wild-type PTEN, expression of this
mutant did not reduce dendritic spine density (Figure 7A), thus
illustrating that the PDZ-binding motif of PTEN was necessary
for this effect. To test whether the C-tail segment of PTEN,
containing the PDZ-binding motif, was sufﬁcient to reduce
dendritic spine density, we expressed a GFP–PTEN-(354–403)
truncation mutant. Strikingly, we observed that expression of this
C-tail segment of PTEN alone reduced dendritic spine density
and that this effect was dependent upon the presence of the PDZ-
binding motif (Figure 7B). Furthermore, we observed no effect
ofthe4Amutation,whereasincorporationofthe4Dmutationinto
the C-tail segment of PTEN blocked its ability to reduce dendritic
spine density (Figure 7B). This indicates that the observed effects
are not artefacts of ectopic expression of PTEN, for example,
loss of substrate speciﬁcity due to overexpression. In contrast, the
results suggest that the phosphorylation of PTEN exerts a direct
inﬂuence on its interaction with PDZ domain-containing proteins
[38,39] and plays an important role in regulating spine density in
this biological assay.
DISCUSSION
The importance of PTEN as a phosphatidylinositol phospholipid-
directed phosphatase, and antagonist of PI3K signalling, is well
established; however, there are additional features of the PTEN
molecule for which the functional signiﬁcance remains to be
fully established, but which may exert regulatory inﬂuence.
Evidence is accumulating to support the classiﬁcation of PTEN
as haploinsufﬁcient, which means that inactivation of one allele,
leaving only one functional copy, is not sufﬁcient to support the
wild-type state [1,2]. Consequently, cells may also be particularly
susceptible to indirect means of functional inactivation of PTEN,
via disruption of regulatory mechanisms [3]. There have been
reports of lipid phosphatase-independent functions of PTEN. For
example, expression of the catalytically dead C124S mutant was
sufﬁcienttoimpairgliomacellinvasion[22]andPTENcaninhibit
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Figure 7 Effect of the PTEN PDZ domain-binding motif on spine density in
neurons
(A) The PTEN PDZ-binding domain is required for the effects of PTEN on spine density in CA1
pyramidal neurons. The effects on spine density of wild-type and mutant PTEN-(1–398), which
lacked the extreme C-terminal ﬁve residues of the protein, were compared. (B) Effects on spine
densityofaPTEN-(354–403)truncationmutant,whichcomprisedonlytheC-terminalsegment
of the protein, were tested to determine the importance of the phosphorylation sites and the
PDZ domain-binding motif in this construct. The top panels are representative images of apical
dendrites of biolistically transfected CA1 pyramidal neurons expressing the indicated forms of
PTEN in organotypic slice cultures of rat hippocampus. Scale bar=10μm. The histograms
show quantiﬁcation of the effects of each plasmid on spine density (means+ −S.E.M., **P <
0.0001). n=8 cells for each group.
gliomacellmigrationthroughitsC2domainalone,intheabsence
of the catalytic domain [21]. In addition, the isolated C2 domain
and catalytically dead forms of PTEN can affect p53 levels [23].
Suchobservationsreinforcetheimportanceofunderstandinghow
these activities of PTEN may be controlled in vivo. In the present
study, we have developed a biological assay of PTEN function on
the basis of its ability to inﬂuence the dendritic spine density of
hippocampal CA1 neurons. We have used it to focus attention on
theproteinphosphataseactivityofPTENanditsimportanceinthe
regulationofthephosphataseitselfbyreversiblephosphorylation.
The identiﬁcation of mutant forms of PTEN in which lipid and
protein phosphatase activities are attenuated selectively [14,20]
has furnished us with a powerful tool with which to explore the
regulation of PTEN function. In particular, the G129E mutant,
in which we ﬁrst demonstrated that lipid phosphatase activity
wasselectivelyablatedleavingproteinphosphataseactivityintact
[14], has been used extensively in the ﬁeld, not only to highlight
the importance of the lipid phosphatase function for the effects of
PTEN on apoptosis [24], cell cycle [25] and resistance of breast
cancer cells to therapeutics [26], but also to reveal the importance
of the protein phosphatase activity in invasion [27], regulation of
the function of Src family kinases [28] and control of the
epithelial–mesenchymal transition [29]. The G129E mutant was
also used to illustrate that PTEN protein phosphatase activity
is important for its effects on NMDA (N-methyl-D-aspartate)
receptor function [30]. We have used the G129E mutant, and
its more recently discovered counterpart, the Y138L mutant [15],
in which protein phosphatase activity is selectively ablated, to
determine which activity, protein or lipid phosphatase, is required
for PTEN-dependent regulation of spine density in organotypic
brain slices. Interestingly, we observed that it was the protein
phosphatase activity that was important; therefore we believe that
spine density can be used as a read-out to assess the role of this
poorly characterized activity of PTEN.
Such studies prompt questions regarding the identity of
the critical protein substrates of PTEN. Initially, there were
suggestions that PTEN may inﬂuence cell migration through
dephosphorylation of the cytoskeletal-associated proteins FAK
(focal adhesion kinase) and p130
CAS [31]. It has also been implic-
ated in dephosphorylation of the PDGF (platelet-derived growth
factor) receptor [32]. However, in our initial characterization of
PTEN, we noted that it demonstrated an unusual speciﬁcity, with
a marked preference for acidic substrates [12]. Various studies
have demonstrated that PTEN is itself a phosphoprotein, and
that the major sites of phosphorylation are found in an acidic
stretch (DHYRYSDTTDSDPENE) near the C-terminus [1]. This
promptedustoconsiderwhetherPTENmayautodephosphorylate
these sites. Indeed, PTEN alleles that maintain protein
phosphatase activity were able to dephosphorylate this peptide
in vitro. Signiﬁcantly, these alleles also exhibited decreased
phosphorylation in vivo, consistent with autodephosphorylation
ofPTEN.Wefoundthatregulationofspinedensitybyectopically
expressed PTEN depended on the phosphorylation status of
the phosphatase, in that expression of a form of PTEN that cannot
bephosphorylatedresultedinadramaticdecreaseinspinedensity,
whereas a form of PTEN that mimics the phosphorylated state
did not. Somewhat surprisingly, the regulation of spine density
by dephospho-PTEN did not require catalytic activity, indicating
that this is a non-catalytic function of PTEN that only required
the catalytic domain for autodephosphorylation.
As might be expected for a motif that is rich in acidic residues,
the C-terminal segment of PTEN is phosphorylated by protein
kinase CK2 [33]. The potential regulatory importance of this
modiﬁcation is suggested by acute changes in phosphorylation
in response to signals, such as leptin [34,35], phosphorylation-
dependent feedback regulation of PTEN following activation
of PI3K-PKB (protein kinase B)/Akt signalling [36] and the
association of PTEN phosphorylation with disease, such as acute
myeloid leukaemia [37]. Various functions have been suggested
for the phosphorylation of PTEN, including control of the
stability of the protein [38] and its susceptibility to cleavage
by caspases [39]. Phosphorylation has also been implicated in
regulating the subcellular distribution and activity state of PTEN.
Initially, it was shown that the segment of PTEN comprising
the PTP and C2 domains has the capacity to direct the protein
to interact with membranes, where it can dephosphorylate its
phospholipid substrate; however, this is regulated by the C-
terminal tail segment, phosphorylation of which was proposed
to serve as an ‘electrostatic switch’ to antagonize membrane
binding [40]. Subsequently, an intramolecular association was
reported between the N-terminal PTP and C2 domains and
the C-terminal portion of the molecule, which results in a
‘closed’ conformation of PTEN that limits its association
with the membrane [41]. Dephosphorylation of the C-terminal
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tail serves to open up the conformation, promoting both
membrane recruitment and activation [42], which, in turn, may
play an important role in determining the distribution of its
phosphatidylinositol phospholipid substrates in the membrane
[43]. Our results suggest that reversible phosphorylation may
also regulate a non-catalytic function of PTEN, its ability to
interact with regulatory proteins via its C-terminal PDZ-binding
domain, which may control its localization, stability and activity
[7]. Several binding proteins have been identiﬁed that have the
potential to regulate PTEN function [7,8]. It has been shown that
phosphorylation of the C-tail segment of PTEN inﬂuences its
ability to interact with the scaffold protein MAGI-2 (membrane-
associated guanylate kinase inverted 2) [44,45]. Interaction with
PICT-1 [protein interacting with C-terminus (of PTEN)-1], which
itself displays properties of a tumour suppressor, is important for
PTEN stability and phosphorylation [46]. There are also binding
proteins with intrinsic kinase activity [47]. Overall, the results of
thepresentstudyrevealthattheC-terminalPDZ-bindingsegment
of PTEN is both necessary and sufﬁcient for the effects of the
phosphatase on spine density in this bioassay. This is consistent
with a model in which the C-terminal segment of PTEN is not
accessibletobindingproteinsinthephosphorylatedstate,whereas
autodephosphorylation promotes association with PDZ domain-
containing proteins. At present the identity of the critical binding
protein(s)remainstobeestablished.Therecentidentiﬁcationofan
interactionbetweenPTENandPSD-95(postsynapticdensitypro-
tein 95), which has been implicated in anchoring the phosphatase
at the postsynaptic membrane during NMDA receptor-dependent
long-term depression, suggests one candidate [48].
In the present study, we have introduced an organotypic
brain slice culture system in which to examine PTEN function.
Although the system is not amenable to biochemical analysis, it
has the advantage of maintaining the tissue architecture of the
hippocampus, producing a ‘mosaic’ that permits analysis of the
transfected neuron in the context of a tissue. By combining this
with two-photon imaging, we have produced a system in which
images with subcellular resolution can be taken, in real-time,
from living tissues, permitting us to use the density of dendritic
spines as a biological read-out of PTEN function. Our results
illustrate that spine density was decreased following ectopic
expression of both wild-type PTEN and the protein phosphatase-
competent G129E mutant; in contrast, catalytically dead (C124S)
and protein phosphatase-deﬁcient but lipid phosphatase-active
(Y138L) mutants were without effect. Furthermore, our results
are consistent with a model in which the PTEN C-tail segment
is itself a substrate of PTEN protein phosphatase activity, with
dephosphorylation of the C-tail being a major requirement
for the reduction in spine density, perhaps through controlling
interactions between PTEN and PDZ domain-containing
proteins. These results reveal a striking parallel with PI3K, which
phosphorylates exogenous lipid substrates and displays protein
kinase activity through autophosphorylation [49], illustrating
symmetry in the regulation of signalling via phosphorylation and
dephosphorylation of inositol phospholipids. It is well known
that PDZ domain proteins play signiﬁcant roles in forming and
maintaining spines in neurons [50]. Our results highlight the
potential signiﬁcance of PTEN itself as a scaffolding protein,
rather than simply being the subject of scaffolding molecules
that target its catalytic function to particular subcellular locales.
Although at present we are only using the effects of PTEN on
spine density as a read-out of phosphatase function in a bioassay,
the identiﬁcation of those proteins that interact with PTEN to
controlspinedensityinthissystemmayalsoprovidenewinsights
into the regulation of neuronal function in normal and disease
states.
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